Autolus and Moderna sign Option and License Agreement for access to proprietary targeting technology from Autolus

NEXT STORY
Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries
PREV STORY
OKYO Pharma Limited Announces final audited results for the year ended 31 March 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO

author_avatar
NASDAQ Market News

CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease

BOSTON and ZUG, Switzerland and CAMBRIDGE, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- CRISPR ...

author_avatar
NASDAQ Market News

ZIOPHARM Oncology to Host Second-Quarter 2017 Financial Results and Corporate Update Conference Call on July 31, 2017 at 4:30 p.m. ET

BOSTON, July 24, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company ...

author_avatar
NASDAQ Market News